Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 10

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Oesophageal adenocarcinoma+2

Recruiting

A study to test the safety and effectiveness of ONA-255 in patients with advanced cancer including breast cancer and gastric cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Ona Therapeutics S.L.

Systemic scleroderma+3

Recruiting

A Study of Idecabtagene Vicleucel CAR-T Cell Therapy for Patients with Autoimmune Diseases That Did Not Respond to B Cell Removal Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Idecabtagene Vicleucel
  • Sponsor:Universitaetsklinikum Erlangen AöR

Gastric cancer+1

Recruiting

Comparing Remimazolam and Propofol for Deep Sedation in Patients Undergoing Endoscopic Ultrasound for Gastric and Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Propofol
  • Sponsor:Ospedale San Raffaele S.r.l.

Endometrial cancer+12

Recruiting

A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zanidatamab
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Adenocarcinoma gastric+2

Recruiting

A study comparing injection under the skin versus infusion into the vein of tislelizumab with chemotherapy for patients with advanced gastric or gastroesophageal junction cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:BeOne Medicines AG

Gastrooesophageal cancer+1

Recruiting

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:FRUQUINTINIB
  • Sponsor:Fondation Franc.Cancerologie Digestive

Adenomatous polyposis coli

Recruiting

A study testing sirolimus to slow disease progression in patients with familial adenomatous polyposis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sirolimus
  • Sponsor:Biodexa Limited

Colorectal adenocarcinoma+2

Recruiting

Study of chemotherapy drug combination with or without heated chemotherapy in the abdomen for patients with advanced colon cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fundacion Para La Investigacion Biomedica De Cordoba

Colitis ulcerative+1

Recruiting

Study of MT-501 in patients with active Crohn's Disease or Ulcerative Colitis: A Phase 2 safety and effectiveness trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Mirador Therapeutics Inc.

Colorectal adenocarcinoma

Recruiting

Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Association Gercor

Rectal cancer

Recruiting

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Adenocarcinoma pancreas

Recruiting

Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.